Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression
Oanh T. P. Nguyen, Sandra Lara, Giovanni Ferro, Matthias Peipp, Sandra Kleinau
This study shows RTX-IgG2 enhances phagocytosis of B-cell lymphoma cells by reducing CD47 expression and promoting apoptosis, improving the efficacy of antibody-based therapies.
Frontiers in Immunology · Dec 6, 2024Peer-reviewedImmunology